CIK 0001701108
- Non-accelerated filer
- Smaller reporting company
Spero Therapeutics, Inc.
Sign in to watch- Ticker
- SPRO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 857-242-1600
- Business address
- 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE, MA, 02139
- Former names
- Spero Therapeutics, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $42,485
- in 1 filing
Net −$42,485. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-11-06 | Goyal Vikas Director | Conversion | +244,147 | 244,147 | ||
| 2017-11-06 | Goyal Vikas Director | Conversion | +246,272 | 490,419 | ||
| 2017-11-06 | Goyal Vikas Director | Conversion | +328,992 | 819,411 | ||
| 2017-11-06 | Goyal Vikas Director | Conversion | +606,024 | 1,425,435 | ||
| 2017-11-06 | Goyal Vikas Director | Purchase | +428,571 | $14.00 | $6.0M | 1,854,006 |
| 2017-11-06 | Goyal Vikas Director | Conversion · Junior preferred stock | −1,483,784 | 0 | ||
| 2017-11-06 | Goyal Vikas Director | Conversion · Series A preferred stock | −982,906 | 0 | ||
| 2017-11-06 | Goyal Vikas Director | Conversion · Series B preferred stock | −1,250,000 | 0 | ||
| 2017-11-06 | Goyal Vikas Director | Conversion · Series C preferred stock | −3,683,045 | 0 | ||
| 2017-11-06 | Sendek Joel Chief Financial Officer | Conversion | +10,181 | 10,181 | ||
| 2017-11-06 | Sendek Joel Chief Financial Officer | Purchase | +5,000 | $14.00 | $70K | 15,181 |
| 2017-11-06 | Sendek Joel Chief Financial Officer | Conversion · Series C Preferred Stock | −61,880 | 0 | ||
| 2017-11-06 | Larkin Cristina Chief Operating Officer | Purchase | +1,500 | $14.00 | $21K | 1,500 |
| 2017-11-06 | Breum Casper Director | Conversion | +289,102 | 289,102 | ||
| 2017-11-06 | Breum Casper Director | Conversion | +179,450 | 468,552 | ||
| 2017-11-06 | Breum Casper Director | Conversion | +408,937 | 877,489 | ||
| 2017-11-06 | Breum Casper Director | Purchase | +214,285 | $14.00 | $3.0M | 1,091,774 |
| 2017-11-06 | Breum Casper Director | Conversion · Series A Preferred Stock | −1,153,846 | 0 | ||
| 2017-11-06 | Breum Casper Director | Conversion · Series B Preferred Stock | −681,818 | 0 | ||
| 2017-11-06 | Breum Casper Director | Conversion · Series C Preferred Stock | −2,485,272 | 0 |
Page 17 of 17 · 340 trades